SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-008516
Filing Date
2023-03-17
Accepted
2023-03-17 17:14:21
Documents
12
Period of Report
2023-03-13
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20230313.htm   iXBRL 8-K 41779
  Complete submission text file 0001628280-23-008516.txt   174980

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20230313.xsd EX-101.SCH 1941
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20230313_lab.xml EX-101.LAB 25133
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20230313_pre.xml EX-101.PRE 13080
6 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20230313_htm.xml XML 4265
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 23743781
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences